Neuroendocrine Tumor

Considering that SSTR expression is also present in various other tumors-including pheochromocytomas, paragangliomas, meningiomas, and medullary thyroid carcinomas-there is increasing interest in expanding the use of PRRT to other SSTR-positive malignancies. This review aimed to present evidence, explore ongoing clinical research, and highlight emerging directions for 177Lu-DOTATATE therapy beyond gastroenteropancreatic NETs.

Both components showed concordant aberrant tumor-suppressor immunoprofiles (p53 overexpression and Rb loss), and high-risk HPV RNA in situ hybridization (RNAscope) was negative. This case expands the recognized morphologic spectrum of bladder neuroendocrine carcinoma to include POU2F3-defined non-small cell neuroendocrine carcinoma with basaloid architecture, supporting the practical value of incorporating POU2F3 into immunohistochemical panels for poorly differentiated basaloid bladder tumors.

The patient died 13 months postoperatively despite chemotherapy. This case highlights that even small NET G3 components in early rectal cancer may indicate poor prognosis.

Pathology confirmed a mixed ductal-neuroendocrine-acinar cell carcinoma in the pancreas and a diffuse large B-cell lymphoma in the kidney and lymph nodes. Pancreatic MiNEN is an extremely rare disease, accounting for only about 0.2% of all pancreatic tumors.

NEN is a tumor that occurs throughout the body, but those that occur in the minor papilla are rare. Because NEN arising from the minor papilla of duodenum has a high rate of lymph node metastasis, pancreaticoduodenectomy with lymph node dissection is recommended.

He was referred for parathyroidectomy followed by total pancreatectomy with duodenectomy, while first-degree relatives were offered genetic screening. This case highlights the diagnostic complexity of MEN1 in the absence of a family history, in which gastrointestinal ulcerations with bleeding, fleeting thrombophlebitis, and hypercalcemia may serve as early clinical clues.

Hsp90α knockdown simultaneously destabilizes EGFR and its downstream AKT/mTOR and ERK axes,resulting in multi-modal suppression of Lactotroph PitNETs invasion.Targeting Hsp90α may offer a novel therapeutic strategy for Aggressive Lactotroph PitNETs refractory to standard medical therapy.

P=N/A, N=450, Recruiting, IRCCS San Raffaele | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026

SEZ6expression is higher in SCLC than in NE tumors, with notable heterogeneity by subtype, warranting consideration of expanded use of SEZ6-directed therapy. Translational Relevance Statement: This study establishes SEZ6 as a promising therapeutic target in small cell lung cancer (SCLC) and transformed non-small cell lung cancer (NSCLC), demonstrating its significantly elevated expression compared to neuroendocrine (NE) tumors and NSCLC. The positive correlation of SEZ6 expression with NE lineage markers, particularly in ASCL1 and NEUROD1 subtypes, highlights its role as a lineage-specific marker, guiding the development of SEZ6-targeted antibody-drug conjugates (ADCs). Additionally, the increased SEZ6 expression following NSCLC-to-SCLC transformation suggests that SEZ6-targeted therapies could address resistance mechanisms in transformed tumors. Importantly, the association between high SEZ6 expression and shorter survival indicates that integrating SEZ6 status into diagnostic workflows could help stratify patients by risk and guide therapeutic decision-making. The findings from this study will inform future clinical trials, aiming to implement SEZ6-targeted treatments as part of precision oncology strategies for aggressive NE malignancies.

The whole-body washout rate derived from pretreatment SSTR imaging is a strong, practical predictor for outpatient eligibility following 177Lu-DOTATATE TRT. Incorporating this simple, noninvasive marker into clinical workflow could support individualized discharge planning and improve patient access under strict radiation safety regulations.

We define three molecular subtypes with distinct outcomes and present an integrative machine learning model combining clinical, genomic, and proteomic features, validated in an independent test dataset of 105 patients and a published dataset. This multi-center, multi-omics study enhances the understanding of MTC heterogeneity and facilitates personalized patient management.

P2, N=24, Completed, Imperial College London | Recruiting --> Completed